Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
An image of Professor Ahmed Ahmed in hospital scrubs.

Professor Ahmed Ahmed is one of the founders of Singula Bio, a seed-stage biotechnology company that was spun out of the University of Oxford and is a current BioEscalator tenant.

The company is focused on developing novel neoantigen-based cell therapies for patients with solid tumours. Singula Bio aims to become a world leader in providing individualised cell therapies for cancer. The company has developed immunological, medical, surgical and computational technologies to develop selective therapies for difficult-to-treat solid malignancies such as ovarian cancer. 

Click here to find out more about Singula Bio



In this interview, Professor Ahmed eloquently and engagingly tells a story about pivotal experiences and a love of rigorous science as he embarked on a journey that took him from studying medicine at Ain Shams University in Cairo to spearheading the development of new cell therapies. 

Click here to read the full interview